SuperworthHeartSciences HSCS
- Market cap
- $15.1M
- PE
- n/m
- one or more of the four quarters through 2026-07-31 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- a sliver of sales
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $4.5K
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Revenue was $4.5K over the last twelve months.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.9K | $14.7K+654% | $0 | n/a | n/a | $0 | $4.3K | $1.9K | $2.4K | $0 | $0 | $2.1K+11% | |
| Cost of revenue | $1.5K | $4.6K+500% | $0 | n/a | n/a | $0 | $1.9K | $760 | $1K | $0 | $0 | $760+0% |
| Gross profit | $2.4K | $10.1K+752% | $0 | n/a | n/a | $0 | $2.5K | $1.1K | $1.4K | $0 | $0 | $1.3K+18% |
| R&D | $757.3K−11% | $509.5K−21% | $1M+96% | $1.2M+117% | $1.2M+58% | $1M+103% | $929.1K−11% | $997.2K−19% | $727K−39% | $638.6K−38% | $476.2K−49% | $906.6K−9% |
| SG&A | $815K−12% | $1M+54% | $833.7K−22% | $850.7K+11% | $786.1K−4% | $1.3M+30% | $993.8K+19% | $878.1K+3% | $1.3M+72% | $1.3M−4% | $2.1M+107% | $2M+132% |
| −$1.6M−12% | −$1.5M+17% | −$1.9M+18% | −$2.1M+56% | −$2M+26% | −$2.4M+56% | −$1.9M+2% | −$1.9M−10% | −$2.1M+5% | −$1.9M−19% | −$2.5M+32% | −$2.9M+57% | |
| Interest expense | $178.4K+444% | $118.4K+261% | $20.9K−38% | $22.5K−38% | $117.6K−34% | $179.5K+52% | $180.9K+764% | $183.7K+715% | $279.5K+138% | $61.5K−66% | $228.3K+26% | $235.3K+28% |
| Net income | −$1.7M−3% | −$1.6M+23% | −$1.8M+13% | −$2.1M+50% | −$2.1M+19% | −$2.5M+54% | −$2.1M+13% | −$2.1M+0% | −$2.4M+13% | −$2M−22% | −$2.8M+31% | −$3.2M+54% |
| −$15.92−28% | −$3.01−81% | −$2.80−84% | −$2.64−80% | −$2.27−86% | −$2.57−15% | −$1.95−30% | −$1.58−40% | −$0.85−63% | n/a | n/a | n/a | |
| 109.8K+34% | 546.7K+563% | 659.3K+577% | 777.7K+653% | 917.4K+735% | 986.1K+80% | 1.1M+63% | 1.3M+68% | 2.8M+203% | n/a | n/a | n/a |
EPS, diluted: 4 periods, Q4 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 276, the two on one basis (x99.81).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Financial - Credit Services nearest HeartSciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HSCSHeartSciences | $15.1M | n/m | n/a | n/m | n/m | n/m | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| RSSSResearch Solutions | $66.2M | 21.8× | 22.2× | 1.4× | −2% | 5.8% | |
| MACIMelar Acquisition Corp. I/Cayman | $105M | 64.7× | 54.4× | n/m | n/m | n/m | |
| Peer median | $24M | 17.9× | 22.2× | 0.8× | +3% | 4.0% |
More on HeartSciences
Each number over time
Its groups
About
- Industry
- Financial - Credit Services
- Sector
- Financial Services
Valuation data, not investment advice. Prices as of .